产品
编 号：F277240
分子式：C22H23FN2O5
分子量：414.43
分子式：C22H23FN2O5
分子量：414.43
产品类型
规格
价格
是否有货
1mg
125
In-stock
5mg
250
In-stock
10mg
400
In-stock
50mg
560
In-stock
100mg
720
In-stock
结构图
CAS No: 219861-08-2
产品详情
生物活性：
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression.
体内研究：
Escitalopram oxalate (10 mg/kg；腹腔注射；每日一次，持续 28 天) 改善应激大鼠的认知障碍并选择性减弱磷酸化 tau 蛋白的积累。长期服用 Escitalopram oxalate (每日一次；饮用水；总共 4 个月) 以 2.5 和 5 mg/d 的剂量分别显著降低斑块负荷 28% 和 34%。Animal Model:Male Sprague-Dawley rats
Dosage:10 mg/kg
Administration:I.p.; daily for 28 days
Result:Could selectively decrease phosphorylated tau accumulation in the hippocampus of stressed rats and could distinctly alleviate the hyperactivity of the HPA axis in both depressive and resistant rats.
Animal Model:APP-PS1 hemizygous female mice (4 months of age)
Dosage:2.5-5 mg/kg
Administration:Daily; drinking water for a total of 4 months
Result:At both doses significantly reduced plaque burden within the brains of these mice compared to littermate controls that drank only water. Hippocampal plaque load was significantly reduced by 28.7% and 34.4 % for ESC 2.5 mg/day and 5 mg/day, respectively.
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression.
体内研究：
Escitalopram oxalate (10 mg/kg；腹腔注射；每日一次，持续 28 天) 改善应激大鼠的认知障碍并选择性减弱磷酸化 tau 蛋白的积累。长期服用 Escitalopram oxalate (每日一次；饮用水；总共 4 个月) 以 2.5 和 5 mg/d 的剂量分别显著降低斑块负荷 28% 和 34%。Animal Model:Male Sprague-Dawley rats
Dosage:10 mg/kg
Administration:I.p.; daily for 28 days
Result:Could selectively decrease phosphorylated tau accumulation in the hippocampus of stressed rats and could distinctly alleviate the hyperactivity of the HPA axis in both depressive and resistant rats.
Animal Model:APP-PS1 hemizygous female mice (4 months of age)
Dosage:2.5-5 mg/kg
Administration:Daily; drinking water for a total of 4 months
Result:At both doses significantly reduced plaque burden within the brains of these mice compared to littermate controls that drank only water. Hippocampal plaque load was significantly reduced by 28.7% and 34.4 % for ESC 2.5 mg/day and 5 mg/day, respectively.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备